Cannara Biotech Balance Sheet Health
Financial Health criteria checks 3/6
Cannara Biotech has a total shareholder equity of CA$81.8M and total debt of CA$48.2M, which brings its debt-to-equity ratio to 58.9%. Its total assets and total liabilities are CA$148.8M and CA$67.0M respectively. Cannara Biotech's EBIT is CA$8.9M making its interest coverage ratio 1.7. It has cash and short-term investments of CA$5.5M.
Key information
58.9%
Debt to equity ratio
CA$48.17m
Debt
Interest coverage ratio | 1.7x |
Cash | CA$5.46m |
Equity | CA$81.77m |
Total liabilities | CA$67.00m |
Total assets | CA$148.77m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 8CB0's short term assets (CA$62.0M) exceed its short term liabilities (CA$26.8M).
Long Term Liabilities: 8CB0's short term assets (CA$62.0M) exceed its long term liabilities (CA$40.2M).
Debt to Equity History and Analysis
Debt Level: 8CB0's net debt to equity ratio (52.2%) is considered high.
Reducing Debt: 8CB0's debt to equity ratio has increased from 30.5% to 58.9% over the past 5 years.
Debt Coverage: 8CB0's debt is well covered by operating cash flow (21.5%).
Interest Coverage: 8CB0's interest payments on its debt are not well covered by EBIT (1.7x coverage).